These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 25323242)

  • 41. [Inhalational antibiotic therapy in patients with cystic fibrosis and Pseudomonas infection].
    Mordasini C; Aebischer CC; Schoch OD
    Schweiz Med Wochenschr; 1997 May; 127(21):905-10. PubMed ID: 9289818
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Skin contamination leading to falsely elevated fingerprick tobramycin levels in a patient taking dry powder inhaled tobramycin.
    Barry PJ; Jones AM
    J Cyst Fibros; 2014 Dec; 13(6):754. PubMed ID: 24795286
    [No Abstract]   [Full Text] [Related]  

  • 43. Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis.
    Govan JR
    J Cyst Fibros; 2002 Dec; 1(Suppl 2):203-8. PubMed ID: 15463836
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis.
    Berlana D; Llop JM; Manresa F; Jódar R
    Pharmacotherapy; 2011 Feb; 31(2):146-57. PubMed ID: 21275493
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus.
    Heijerman H; Westerman E; Conway S; Touw D; Döring G;
    J Cyst Fibros; 2009 Sep; 8(5):295-315. PubMed ID: 19559658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
    Taccetti G; Bianchini E; Cariani L; Buzzetti R; Costantini D; Trevisan F; Zavataro L; Campana S;
    Thorax; 2012 Oct; 67(10):853-9. PubMed ID: 22379071
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.
    Pesaturo KA; Horton ER; Belliveau P
    Ann Pharmacother; 2012; 46(7-8):1076-85. PubMed ID: 22764322
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology.
    Geller DE; Weers J; Heuerding S
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):175-82. PubMed ID: 21395432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).
    Oermann CM; McCoy KS; Retsch-Bogart GZ; Gibson RL; McKevitt M; Montgomery AB
    J Antimicrob Chemother; 2011 Oct; 66(10):2398-404. PubMed ID: 21784781
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose administration maneuvers and patient care in tobramycin dry powder inhalation therapy.
    Buttini F; Balducci AG; Colombo G; Sonvico F; Montanari S; Pisi G; Rossi A; Colombo P; Bettini R
    Int J Pharm; 2018 Sep; 548(1):182-191. PubMed ID: 29883795
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NICE guidance on colistimethate sodium and tobramycin for pseudomonas lung infection in cystic fibrosis.
    Nolan K; Knight H; Clark P
    Lancet Respir Med; 2013 Apr; 1(2):102-3. PubMed ID: 24429083
    [No Abstract]   [Full Text] [Related]  

  • 52. Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
    Ratjen F; Döring G; Nikolaizik WH
    Lancet; 2001 Sep; 358(9286):983-4. PubMed ID: 11583754
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin.
    Vecellio L; Abdelrahim ME; Montharu J; Galle J; Diot P; Dubus JC
    J Cyst Fibros; 2011 Mar; 10(2):86-92. PubMed ID: 21075063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis.
    Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M
    Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inhaled aztreonam lysine: an evidence-based review.
    Hutchinson D; Barclay M; Prescott WA; Brown J
    Expert Opin Pharmacother; 2013 Oct; 14(15):2115-24. PubMed ID: 23992352
    [TBL] [Abstract][Full Text] [Related]  

  • 56. After a long wait, two arrive, one after the other!
    Southern KW; McCormack P; McNamara PS
    Thorax; 2013 Apr; 68(4):311-2. PubMed ID: 23299961
    [No Abstract]   [Full Text] [Related]  

  • 57. Nebulisers comparison with inhaled tobramycin in young children with cystic fibrosis.
    Clavel A; Boulaméry A; Bosdure E; Luc C; Lanteaume A; Gorincour G; Stremler-Lebel N; Sarles J; Andrieu V; Dubus JC
    J Cyst Fibros; 2007 Apr; 6(2):137-43. PubMed ID: 16839826
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Inhaled interventions in cystic fibrosis: mucoactive and antibiotic therapies.
    Hurt K; Bilton D
    Respiration; 2014; 88(6):441-8. PubMed ID: 25472021
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aztreonam lysine for inhalation: new formulation of an old antibiotic.
    Zeitler K; Salvas B; Stevens V; Brown J
    Am J Health Syst Pharm; 2012 Jan; 69(2):107-15. PubMed ID: 22215356
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Desensitization to inhaled aztreonam lysine in an allergic patient with cystic fibrosis using a novel approach.
    Guglani L; Abdulhamid I; Ditouras J; Montejo J
    Ann Pharmacother; 2012 Oct; 46(10):e25. PubMed ID: 23012384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.